Skip to main content

Advertisement

SpringerLink
Log in

HIPEC Trials and the US: A Review and Call to Action

  • Peritoneal Surface Malignancy
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. National Comprehensive Cancer Network. Colon Cancer (Version 4.2020). Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 11 Sep 2020.

  2. Morton DL, Ollila DW, Hsueh EC, Essner R, Gupta RK. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin. 1999;49(2):101–16. https://doi.org/10.3322/canjclin.49.2.101.

    Article  CAS  PubMed  Google Scholar 

  3. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40(2):256–60.

    CAS  PubMed  Google Scholar 

  4. Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985;98(3):414–22.

    CAS  PubMed  Google Scholar 

  5. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Annals Surg. 1995;221(2):124–32. https://doi.org/10.1097/00000658-199502000-00002.

    Article  CAS  Google Scholar 

  6. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Annals Surg Oncol. 1999;6(8):790–6. https://doi.org/10.1007/s10434-999-0790-0.

    Article  CAS  Google Scholar 

  7. Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery. 1993;113(6):631–6.

    CAS  PubMed  Google Scholar 

  8. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545–50. https://doi.org/10.1046/j.1365-2168.2002.02274.x.

    Article  CAS  PubMed  Google Scholar 

  9. Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003;21(5):799–806. https://doi.org/10.1200/JCO.2003.06.139.

    Article  CAS  PubMed  Google Scholar 

  10. Jacquet P, Stephens AD, Averbach AM, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer. 1996;77(12):2622–9. https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12%3c2622::AID-CNCR28%3e3.0.CO;2-T.

    Article  CAS  PubMed  Google Scholar 

  11. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92. https://doi.org/10.1200/JCO.2004.10.012.

    Article  CAS  PubMed  Google Scholar 

  12. Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Archiv Surg. s2003;138(1):26–33. https://doi.org/10.1001/archsurg.138.1.26.

    Article  CAS  Google Scholar 

  13. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560–7. https://doi.org/10.1200/JCO.2003.04.150.

    Article  CAS  PubMed  Google Scholar 

  14. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63. https://doi.org/10.1002/(sici)1097-0142(20000115)88:2%3c358::aid-cncr16%3e3.0.co;2-o.

    Article  CAS  PubMed  Google Scholar 

  15. Marcus EA, Weber TK, Rodriguez-Bigas MA, Driscoll D, Meropol NJ, Petrelli NJ. Prognostic factors affecting survival in patients with colorectal carcinomatosis. Cancer Investig. 1999;17(4):249–52. https://doi.org/10.3109/07357909909040593.

    Article  CAS  Google Scholar 

  16. Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Annals Surg Oncol. 2004;11(5):518–21. https://doi.org/10.1245/ASO.2004.09.008.

    Article  Google Scholar 

  17. Cashin PH, Mahteme H, Spang N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155–62. https://doi.org/10.1016/j.ejca.2015.09.017.

    Article  CAS  PubMed  Google Scholar 

  18. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. https://doi.org/10.1200/JCO.2003.04.187.

    Article  PubMed  Google Scholar 

  19. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Annals Surg Oncol. 2008;15(9):2426–32. https://doi.org/10.1245/s10434-008-9966-2.

    Article  Google Scholar 

  20. Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Annals Surg Oncol. 2009;16(8):2152–65. https://doi.org/10.1245/s10434-009-0487-4.

    Article  Google Scholar 

  21. Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36(18 Suppl):LBA3503. https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA3503.

    Article  Google Scholar 

  22. Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Annals Oncol. 2004;15(10):1558–65. https://doi.org/10.1093/annonc/mdh398.

    Article  CAS  Google Scholar 

  23. Goere D, Glehen O, Quenet F, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020;21(9):1147–54. https://doi.org/10.1016/S1470-2045(20)30322-3.

    Article  CAS  PubMed  Google Scholar 

  24. Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761–70. https://doi.org/10.1016/S2468-1253(19)30239-0.

    Article  PubMed  Google Scholar 

  25. van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. New Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618.

    Article  PubMed  Google Scholar 

  26. Foster JM, Sleightholm R, Patel A, et al. Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open. 2019;2(1):e186847. https://doi.org/10.1001/jamanetworkopen.2018.6847.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Levine EA, Votanopoulos KI, Shen P, et al. A Multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am College Surg. 2018;226(4):434–43. https://doi.org/10.1016/j.jamcollsurg.2017.12.027.

    Article  Google Scholar 

  28. de Jong LAW, Elekonawo FMK, de Reuver PR, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. Br J Clin Pharmacol. 2019;85(1):47–58. https://doi.org/10.1111/bcp.13773.

    Article  PubMed  Google Scholar 

  29. De Somer F, Ceelen W, Delanghe J, et al. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int. 2008;28(1):61–6.

    Article  Google Scholar 

  30. Rueth NM, Murray SE, Huddleston SJ, et al. Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Annals Surg Oncol. 2011;18(1):174–80. https://doi.org/10.1245/s10434-010-1210-1.

    Article  Google Scholar 

  31. Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709–19. https://doi.org/10.1016/S1470-2045(16)30500-9.

    Article  PubMed  Google Scholar 

  32. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5. https://doi.org/10.1200/JCO.2008.19.7160.

    Article  PubMed  Google Scholar 

  33. Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Annals Surg Oncol. 2014;21(5):1501–5. https://doi.org/10.1245/s10434-013-3061-z.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

None.

Funding

No sources of funding were used to assist in the preparation of this review.

Author information

Authors and Affiliations

  1. Professor of Surgery, Penn State College of Medicine, Hershey, PA, USA

    Colette R. Pameijer MD

Authors
  1. Colette R. Pameijer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CP is the sole author of this manuscript and is responsible for the concept, data acquisition, interpretation of studies, and writing of the manuscript.

Corresponding author

Correspondence to Colette R. Pameijer MD.

Ethics declarations

Discloure

Colette R. Pameijer has no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pameijer, C.R. HIPEC Trials and the US: A Review and Call to Action. Ann Surg Oncol 29, 866–872 (2022). https://doi.org/10.1245/s10434-021-10769-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10769-6

Keywords

Search

Navigation